Revel Pharmaceuticals develops therapies that target the excess accumulation of toxic proteins and metabolites, aiming to repair age-related damage and complications from chronic diseases such as osteoarthritis and diabetes. By addressing the root causes of aging and chronic illness, their solutions offer a pathway to reverse disease progression and improve patient outcomes.
Funding
$10.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KTSCFounders
Product
Problem
Many age-related diseases and chronic illnesses are caused by the accumulation of toxic proteins or metabolites within the body. This buildup contributes to cellular damage and impaired function, driving disease progression.
Solution
Revel Pharmaceuticals develops targeted therapies designed to address the root causes of aging and chronic diseases by clearing toxic protein and metabolite buildup. Their approach focuses on repairing the damage caused by these accumulations and reversing the course of disease. By targeting the underlying mechanisms of aging and chronic illness, Revel aims to restore cellular function and improve patient outcomes.
Target Audience
The primary target audience includes individuals suffering from age-related diseases and chronic illnesses, as well as healthcare providers seeking innovative therapies to address the underlying causes of these conditions.
Features
- Therapies designed to clear specific toxic proteins and metabolites.
- Focus on repairing cellular damage caused by toxic accumulations.
- Development of solutions to reverse the progression of age-related diseases and chronic illnesses.